Clinical-grade psilocybin Phase IIb trials
With $9.5m cash and no debt, the company strengthens vertical integration as clinical-grade psilocybin Phase IIb trials advance toward scale and value creation.
psyencebiomed.comCrawled Nov 19, 2026
With $9.5m cash and no debt, the company strengthens vertical integration as clinical-grade psilocybin Phase IIb trials advance toward scale and value creation.
Psyence BioMed achieves GMP ibogaine HCl production from natural sources while strengthening its balance sheet with no debt and $12m cash.
Psyence BioMed explores how psilocybin may influence aging, cellular resilience, and human longevity, offering a new approach to long term vitality.
Published on States of Mind this article is written by Stephanie Price and clinically reviewed by Christian Snuffer, a Clinical Mental Health Counselor.
This corporate webinar will provide investors and stakeholders with a unique opportunity to engage directly with Psyence Biomed’s leadership
Psyence Biomed Ltd began trading on Nasdaq under the ticker **PBM** after merging with Newcourt Acquisition Corp.
Biomedical News - The latest psychedelic and psilocybin industry news from The Psyence Biomed company.
Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
Psyence Group Announces SEC Effectiveness Of F-4 For Proposed Business Combination Between Subsidiary And NASDAQ Listed Newcourt Acquisitions Corp
Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination
Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement
Psyence BioMed (Nasdaq: PBM) is advancing ibogaine- and psilocybin-based neuroplastogen therapeutics to address significant unmet medical needs.